Vertex Pharmaceuticals
Boston
Massachusetts
United States
784 articles about Vertex Pharmaceuticals
-
Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older
5/3/2023
Vertex Announces U.S. FDA Approval for KALYDECO ® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older.
-
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
4/26/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to TRIKAFTA® based on in vitro data.
-
Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9
4/25/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET.
-
The regulatory filing puts the company alongside Vertex and CRISPR, which also await FDA approval for their SCD gene therapy. -
Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials. -
Vertex Announces Health Canada Market Authorization for ORKAMBI& (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 1 to 2 Years
4/10/2023
Vertex Pharmaceuticals ( Canada ) Incorporated (Nasdaq: VRTX) today announced that Health Canada, as a partner of the Access Consortium, has granted Marketing Authorization for the expanded use of PrORKAMBI® (lumacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in children ages 1 to <2 years who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
-
Vertex to Announce First Quarter 2023 Financial Results on May 1
4/10/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close.
-
In a potential leap forward for sickle cell disease, Vertex moved closer to launching its one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia. -
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
4/3/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
-
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
3/27/2023
Vertex Pharmaceuticals Incorporated today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D).
-
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
3/16/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants.
-
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes. -
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
2/21/2023
Vertex Pharmaceuticals Incorporated announced that management will present at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET.
-
Vertex Pharmaceuticals is marching toward the launch of exa-cel with a lot of confidence, per its full-year 2022 presentation. -
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
2/9/2023
Entrada Therapeutics, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and closing of the Company’s previously announced strategic collaboration and license agreement with Vertex.
-
Amid growing demands for generic versions of Vertex’s Trikafta, the company provided an update on the late-stage clinical development of its next-in-class triple combination for cystic fibrosis.
-
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
2/7/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2022 and provided full year 2023 financial guidance.
-
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
1/17/2023
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close.
-
Vertex and Arbor Biotechnologies extend partnership in precision gene editing.
-
2022's Top Clinical Advancements: See Pivotal Data in NASH, Alzheimer’s, Sickle Cell Disease
12/23/2022
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.